{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:23:50Z","timestamp":1778747030935,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clinthera.2021.09.013","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T01:58:10Z","timestamp":1635818290000},"page":"1983-1996.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study"],"prefix":"10.1016","volume":"43","author":[{"given":"Sujith","family":"Dhanasiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Hollier-Hann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Stothard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devender S.","family":"Dhanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.09.013_bib0001","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study","volume":"18","author":"Mohty","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0002","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0003","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjh.15680","article-title":"Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016","volume":"185","author":"Raab","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0006","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0007","first-page":"2789","article-title":"Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life","volume":"23","author":"Baz","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0008","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0009","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0010","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.09.013_bib0011","first-page":"476","article-title":"A systematic literature review to assess efficacy of treatments in triple-class exposed relapsed and refractory multiple myeloma patients [EP1033]","volume":"4","author":"Davies","year":"2020","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.09.013_bib0012","first-page":"807","article-title":"Recent treatment patterns, healthcare utilization, and costs in heavily pretreated relapsed and\/or refractory multiple myeloma patients in the United States [EP1756]","volume":"4","author":"Chari","year":"2020","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2021.09.013_bib0013","first-page":"475","article-title":"Patient characteristics, treatment patterns and outcomes in patients with triple class refractory multiple myeloma [EP1032]","volume":"4","author":"Mehra","year":"2020","journal-title":"HemaSphere"},{"issue":"Suppl 15","key":"10.1016\/j.clinthera.2021.09.013_bib0014","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1200\/JCO.2020.38.15_suppl.8525","article-title":"KarMMa-RW: a study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa","volume":"38","author":"Jagannath","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0015","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/fon-2020-1003","article-title":"Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA","volume":"17","author":"Madduri","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0016","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/13696998.2017.1421546","article-title":"Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy","volume":"21","author":"Gonzalez-McQuire","year":"2018","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0017","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1177\/1078155219881489","article-title":"Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events","volume":"26","author":"Ailawadhi","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0018","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","article-title":"Next-generation multiple myeloma treatment: a pharmacoeconomic perspective","volume":"128","author":"Rajkumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0019","series-title":"SHELF: the Sheffield Elicitation Framework (version 4)","author":"Oakley","year":"2019"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clinthera.2019.01.009","article-title":"Cost offsets in the treatment journeys of patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Ailawadhi","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0021","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0022","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2019.100243","article-title":"Unplanned admissions for patients with myeloma in the UK: low frequency but high costs","volume":"17","author":"Kolovos","year":"2019","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0024","article-title":"Darzalex [daratumumab], summary of product characteristics","year":"2019","journal-title":"Amsterdam: European Medicines Agency"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s10198-020-01219-3","article-title":"Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany","volume":"21","author":"Basic","year":"2020","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.clinthera.2021.09.013_bib0026","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/NCC.0b013e3182693522","article-title":"Personal financial effects of multiple myeloma and its treatment","volume":"36","author":"Goodwin","year":"2013","journal-title":"Cancer Nurs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821003866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:16Z","timestamp":1758963376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821003866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0149291821003866"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.09.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}